The debate over whether activated Ras can regulate phosphoinositide-specific phospholipase C (PLC) has been contentious and at times heated. The argument may be resolved by the recent identification of a novel Ras-regulated PLC, but some unexpected properties of this protein are sure to stimulate further controversy.
The Ras proteins are small GTP-binding proteins that have achieved notoriety as products of genes that are found mutated in approximately 15% of all human tumours [1] . In cells harbouring a Ras oncogene, the Ras oncoprotein is locked in the GTP-bound active conformation as a result of a defective GTPase activity. In this state, Ras is constitutively active and can transmit signals for proliferation, differentiation and oncogenesis in the absence of cellular stimulation. To fully appreciate how Ras signals downstream, there is a need to identify the proteins that interact directly with the active GTP-bound form of Ras.
Among the pathways that signal downstream from activated Ras, the one that starts with the serine-threonine kinase Raf and follows with activation of the ERK mitogenactivated protein (MAP) kinases, remains of key importance for many facets of Raf biology. However, it is now well appreciated that Ras uses a multitude of downstream effectors, in addition to Raf, to cause its diverse biological actions. The biochemically and genetically best-characterised of these are the phosphoinositide 3-kinases (PI 3-kinases) and members of the Ral guanine nucleotide exchange factor (RalGEF) family (reviewed in [2] ). Results reported recently suggest that this select group has now been joined by phosphoinositide-specific phospholipase C epsilon (PLCε) -a novel PLC that binds to, and is regulated by, activated Ras [3] [4] [5] [6] .
Phosphoinositide-specific PLCs are a family of enzymes that regulate the hydrolysis of the inner plasma membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP 2 ) [7] . This reaction yields two intracellular second messengers, diacylglycerol and inositol 1,4,5-trisphosphate (IP 3 ), which induce, respectively, activation of protein kinase C and the release of internally stored Ca 2+ . Prior to the discovery of PLCε, ten mammalian PLC isoforms had been identified: PLCβ1-4, PLCδ1-4 and PLCγ1-2, all of which contain a δ-like core, composed of two regions of high sequence similarity (X and Y) which together constitute the PLC catalytic domain, a pleckstrin homology (PH) domain, an EF-hand domain, and a C2 domain (Figure 1 ) [7] . Besides this δ-like core, the β isozymes have carboxy-terminal extensions of around 400 residues, and the γ isozymes have an insertion of about 500 residues between the two halves of the catalytic domain. These structural differences are linked to the distinct mode of regulation for each isozyme: association with heterotrimeric G proteins of the Gq family stimulates the β isozymes, whereas the γ isozymes, which contains Src homology (SH2 and SH3) domains, are activated by receptor or cytosolic tyrosine kinases. The mechanism of regulation of PLCδ is less clear, but changes in intracellular Ca 2+ may be involved [7] .
Sequence analysis of human [4, 5] , rat [6] and Caenorhabditis elegans [3] forms of PLCε showed that, whereas the centrally located X and Y domains and the C2 domain are highly conserved in this isozyme, the PH and EF-hand domains are absent. At the molecular level, however, the diagnostic features of PLCε are the presence of an aminoterminal Ras GTP exchange factor domain and two carboxy-terminal Ras-association domains, RA1 and RA2. This unique structural organisation clearly suggests that PLCε represents a novel fourth class of mammalian PLC isoforms. Interestingly, the human PLCε described by Lopez et al. [4] has an amino-terminal deletion of approximately 304 amino acids compared with the one cloned by Song et al. [5] . Although this deletion does not remove any of the functional domains, it does suggest the existence of at least two splice variants of human PLCε.
From the degree of conservation with other Ras effectors, one would predict that the RA domains of PLCε should bind activated Ras. Indeed, the RA2 domain of PLCε was found to bind Ras in a GTP-dependent manner, with an affinity comparable to the binding of Ras to Raf-1 [6] . Furthermore, the RA2 domain is typical of other Rasbinding domains in that it interacts with Ras through residues predicted by structural and functional analysis to be important in other Ras effectors [8] . For instance, mutation of a single lysine residue critical for Ras binding to other RA domains [8] -K2150 in rat PLCε -inhibits Ras binding to the RA2 domain [6] . Finally, like its binding to other Ras effectors, Ras binds to the RA2 domain of PLCε through its effector domain, as mutations in this regionsuch as T35S and Y40C -inhibit binding [6] .
So clearly the RA2 domain of PLCε binds to activated Ras. But what is the significance of this interaction in terms of the ability of PLCε to hydrolyse PIP 2 ? To address this question, Kelley et al. [6] examined the activity of PLCε in COS-7 cells in the presence or absence of a constitutively active mutant form of H-Ras. They not only found that the mutant Ras markedly stimulated the PLC activity of PLCε, but observed a complete correlation between the mutational effects on Ras binding to the RA2 domain and the resulting ability of Ras to stimulate the enzymatic activity of PLCε [6] . Such an elegant analysis provides strong evidence that the binding of activated Ras to the RA2 domain results in activation of PLCε. The criteria for being a genuine Ras effector -namely the ability to bind to and be regulated by activated Ras -are thus fulfilled by PLCε. (Note, for those researchers using the various Ras effector mutants to specifically activate a given Ras effector, it is important to consider that the E37G mutant stimulates PLCε and should therefore not be considered as specifically activating RalGDS; furthermore, the D38N mutant -up to now considered a universal inhibitorsignificantly activates PLCε [6] .)
The precise mechanism by which Ras activates its effectors is currently unclear. For instance, the mechanism of Raf-1 activation is complex, requiring the Ras-induced translocation of Raf-1 to the plasma membrane, induction of a conformational change and modification by phosphorylation (see [9] for a current model). For the purposes of this discussion, however, it is notable that evidence is accumulating to suggest that Ras activates Raf-1 by binding to two Ras-binding domains [10, 11] . In addition to the high-affinity RA domain, Raf-1 also has an adjacent cysteine-rich domain (CRD) that binds Ras in a GTP-independent manner. It has been proposed that Ras interaction with this domain is critical for Ras activation of Raf-1 -a similar requirement for dual Ras binding sites appears necessary for Ras activation of yeast adenylyl cyclase [12] .
Given that PLCε has two RA domains, can a similar model account for the Ras-mediated activation of PLCε? A number of observations are consistent with this. First, for Ras to activate PLCε it must be post-translationally modified [6] . Secondly, activated Ras can induce the plasma membrane translocation of cytosolic PLCε [5] . Finally, the RA1 domain of PLCε is not only similar to the CRD of Raf-1, in that it binds Ras with a low affinity and in a GTP-independent manner [6] , but it is also required for Ras-mediated activation of PLCε [6] . Thus, the mechanism for Ras activation of PLCε is certainly complex, involving translocation and/or activation via the tandem RA domains.
Activated Ras may not, however, be the sole regulator of PLCε. As with a number of other Ras effectors, the RA2 domain of PLCε also binds the GTP-bound form of the Ras-related protein Rap1A -this results from Rap1A having an effector domain virtually identical to that of Ras [5, 6] . Although this interaction may target PLCε to a perinuclear localisation, rather than the plasma membrane [5] , its physiological relevance remains to be established. Lopez et al. [4] also suggest that PLCε is one of the few effectors for the G 12/13 family of heterotrimeric G-proteins. These highly oncogenic G proteins -a GTPase deficient mutant of Gα 12 can fully transform NIH3T3 A diagrammatic representation of the newly expanded family of mammalian PLC isozymes. The various molecular domains, and the possibility of two human PLCε splice variants (tentatively termed PLCε1 and PLCε2) are discussed further in the text. [19] reported independent evidence that an increase in the level of inositol phosphates could be detected in cells expressing activated Ras. This result -indicative of an increase in PLC activity -led the authors to suggest that activated Ras lay upstream of PLC [18] [19] [20] . At the time, these data were viewed as extremely controversial, and they subsequently have been largely ignored (see for example [21, 22] ). The identification of PLCε rekindles interest in these data, and may in fact validate the basic conclusion drawn by Cantley and Wakelam. Irrespective of this, the really important point is that the characterisation of PLCε as a Ras effector has again placed PLC in the spotlight of Ras biology. As with other Ras effectors, the next crucial step is to establish the role of PLCε in transmitting signals from activated Ras through to changes in proliferation, differentiation and oncogenesis. As Ras most likely uses distinct sets of effectors in a combinatorial fashion to effect its diverse biological actions, this will be an exciting, but challenging problem.
